AU2014221268A1 — Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino] -pyrimidin-4-yl}-1-methyl-urea and salts thereof.
Assigned to Novartis AG · Expires 2014-09-25 · 12y expired
What this patent protects
H:\dx -n vlovero RPorthl\DCCRBR\ 5 Loc4/09/20!4 The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6 dichi oro-3 ,5-dim ethoxy-phenyl')-I -(6-[4-(4-ethyl-piperazin- 1-yl)-phenylamino] -pyrimidin -yl}-1-methyl-urea, amorphous and anhydrous cryst…
USPTO Abstract
H:\dx -n vlovero RPorthl\DCCRBR\ 5 Loc4/09/20!4 The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6 dichi oro-3 ,5-dim ethoxy-phenyl')-I -(6-[4-(4-ethyl-piperazin- 1-yl)-phenylamino] -pyrimidin -yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt, and the hydrochloride salt, including its dihydrate. The present technology further provides methods for preparing the various forms, compositions containing them, and methods of treatment employing them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.